Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry

[1]  M. Miravitlles,et al.  Demographic and clinical characteristics of patients with α1-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO , 2022, ERJ Open Research.

[2]  T. Greulich,et al.  Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews , 2022, European Respiratory Review.

[3]  M. Miravitlles,et al.  Association between circulating alpha-1 antitrypsin polymers and lung and liver disease , 2021, Respiratory Research.

[4]  R. Tsonaka,et al.  Long-term effect of α1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database , 2021, ERJ Open Research.

[5]  T. Greulich,et al.  Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration , 2020, ERJ Open Research.

[6]  M. Miravitlles,et al.  Prevalence of α1-antitrypsin PiZZ genotypes in patients with COPD in Europe: a systematic review , 2020, European Respiratory Review.

[7]  A. Turner,et al.  Why is Disease Penetration so Variable in Alpha-1 Antitrypsin Deficiency? The Contribution of Environmental Factors. , 2020, Chronic obstructive pulmonary diseases.

[8]  M. Miravitlles,et al.  Spanish Implementation of the New International Alpha-1 Anitrypsin Deficiency International Registry: The European Alpha-1 Research Collaboration (EARCO). , 2020, Archivos de bronconeumologia.

[9]  M. Miravitlles,et al.  Implementation of European Alpha-1 Research Collaboration (EARCO) in Portugal: the future starts now. , 2020, Pulmonology.

[10]  D. DeLuca,et al.  Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population. , 2020, Archivos de bronconeumologia.

[11]  M. Henry,et al.  Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency , 2020, Thorax.

[12]  A. Yorgancioglu,et al.  Protocol for the EARCO Registry: a pan-European observational study in patients with α1-antitrypsin deficiency , 2020, ERJ Open Research.

[13]  E. Piitulainen,et al.  Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency , 2019, International journal of chronic obstructive pulmonary disease.

[14]  R. Stockley,et al.  The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency , 2019, European Respiratory Journal.

[15]  I. Horváth,et al.  Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey , 2019, ERJ Open Research.

[16]  I. Horváth,et al.  The importance of effective registries in pulmonary diseases and how to optimize their output , 2019, Chronic respiratory disease.

[17]  A. Dirksen,et al.  European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency , 2017, European Respiratory Journal.

[18]  C. Vogelmeier,et al.  Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency. , 2017, Respiratory medicine.

[19]  E. Silverman,et al.  Serum Proteins Associated with Emphysema Progression in Severe Alpha-1 Antitrypsin Deficiency. , 2017, Chronic obstructive pulmonary diseases.

[20]  M. Miravitlles,et al.  Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics , 2017, International journal of chronic obstructive pulmonary disease.

[21]  M. Miravitlles,et al.  Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update , 2017, International journal of chronic obstructive pulmonary disease.

[22]  R. Stockley,et al.  Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management? , 2016, International journal of chronic obstructive pulmonary disease.

[23]  Berend C Stoel,et al.  Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[24]  E. Piitulainen,et al.  The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency , 2015, COPD.

[25]  R. Stockley,et al.  Spirometric and gas transfer discordance in a α1 -antitrypsin deficiency. patient characteristics and progression. , 2014, Chest.

[26]  M. Miravitlles,et al.  Clinical phenotypes of Italian and Spanish patients with &agr;1-antitrypsin deficiency , 2012, European Respiratory Journal.

[27]  T. Greulich,et al.  The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency , 2012, International journal of chronic obstructive pulmonary disease.

[28]  Joseph B Stanford,et al.  The Physical Activity Vital Sign: a primary care tool to guide counseling for obesity. , 2010, Journal of physical activity & health.

[29]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[30]  R. Stockley,et al.  Rate of progression of lung function impairment in α1-antitrypsin deficiency , 2009, European Respiratory Journal.

[31]  M. Simmonds,et al.  The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency , 2008, Respiratory research.

[32]  D. DeMeo,et al.  Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency , 2007, Thorax.

[33]  R. Stockley,et al.  Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development , 2007, European Respiratory Journal.

[34]  R. Stockley,et al.  The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. , 2002, American journal of respiratory and critical care medicine.

[35]  E. Piitulainen,et al.  Environmental correlates of impaired lung function in non-smokers with severe α1-antitrypsin deficiency (PiZZ) , 1998, Thorax.

[36]  Peter C Gøtzsche,et al.  Alpha1-antitrypsin deficiency. , 2009, The New England journal of medicine.

[37]  R. Stockley,et al.  Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. , 2007, American journal of respiratory and critical care medicine.

[38]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[39]  Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. , 1998, American journal of respiratory and critical care medicine.

[40]  R. S. Sen,et al.  Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin , 1998 .

[41]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.